Entresto Risk Sharing Could Equate To 8.6% Discount, ICER Says; Is Express Scripts Interested?
This article was originally published in The Pink Sheet Daily
Executive Summary
Cost effectiveness report on Novartis’ new heart failure drug includes a hypothetical risk-sharing payment model using hospitalization or death as patient endpoints; Express Scripts exec notes outcomes-based contracts have been problematic but hints at potential for Entresto.
You may also be interested in...
Novartis' Entresto: Slow Uptake Expected Following Fast FDA Approval
Reimbursement complexity and physician reluctance to move stable patients off their current treatment regimens are the biggest hurdles.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.
Biden vs Trump On Drug Pricing And Unfinished Business
While more significant reforms are less likely under a second Biden term unless Democrats control both chambers of Congress, former President Trump could look to put his stamp on drug pricing reform by resurrecting one of his former policies involving international reference pricing and Medicare Part B drugs.